Table 2.
Characteristics of the included studies and baseline patient information.
| Author | Year | Patients (knees) | Sex (male/female) | Age (year) | Follow‐up time (months) | Research type | Level of evidence | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DB | SB | DB | SB | DB | SB | DB | SB | ||||
| Astur et al. [3] | 2015 | 28 (28) | 30 (30) | 30/28 | 28.3 (18–45) | 31.1 (18–45) | 60 | RCT | Ⅰ | ||
| Ercan et al. [7] | 2021 | 40 (40) | 40 (40) | 18/22 | 20/20 | 19 (14–29) | 15 (10–28) | 40 (24–74) | 46.5 (24–74) | RCT | Ⅰ |
| Gao et al. [9] | 2015 | 17 (17) | 12 (12) | 11/18 | 24 (15–36) | 14 | CS | Ⅲ | |||
| Guo et al. [10] | 2018 | 50 (50) | 44 (44) | 32/18 | 26/18 | 49.5 ± 9.3 | 49.6 ± 9.2 | 12 | CS | Ⅲ | |
| Li et al. [18] | 2018 | 25 (25) | 22 (22) | 10/15 | 7/5 | 16–30 | 16–33 | 39 | CS | Ⅲ | |
| Li et al. [19] | 2019 | 45 (45) | 43 (43) | 15/30 | 17/26 | 26.9 ± 5.4 | 27.4 ± 5.6 | 40.9 ± 7.2 | 41.3 ± 7.5 | RCT | Ⅰ |
| Liu et al. [20] | 2018 | 36 (36) | 33 (33) | 8/28 | 7/26 | 17.9 ± 4.3 | 18.5 ± 3.5 | 24 ± 2.1 | CS | Ⅲ | |
| Mohammed et al. [22] | 2017 | 26 (29) | 27 (29) | 8/18 | 12/15 | 22.8 ± 8.5 | 20.9 ± 7.7 | Undescribed | CS | Ⅲ | |
| Qiao et al. [28] | 2022 | 42 (42) | 48 (48) | 15/27 | 16/32 | 21.4 (14–41) | 23.8 (15–39) | 38.6 (25–53) | 37.8 (27–50) | RCT | Ⅰ |
| Sun et al. [30] | 2016 | 38 (38) | 40 (40) | 12/26 | 16/24 | 20.5 ± 3.3 | 20.2 ± 3.7 | 12 (10–14) | CS | Ⅲ | |
| Wang et al. [32] | 2013 | 37 (44) | 21 (26) | 16/21 | 7/14 | 26 ± 7 | 23 ± 10 | 12 and 48 | CS | Ⅲ | |
| Wang et al. [33] | 2010 | 38 (45) | 22 (27) | 10/15 | 7/15 | 16–30 | 16–33 | 39 | CS | Ⅲ | |
| Wu et al. [35] | 2017 | 26 (26) | 32 (32) | 7/19 | 10/22 | 21.8 (16–28) | 22.5 (16–28) | 23.9 (18–30) | CS | Ⅲ | |
Abbreviations: DB, double‐bundle; RCS, retrospective cohort study; RCT, randomized controlled trials; SB, single‐bundle.